Company intelligence / Profile preview

Zydus Pharmaceuticals

Pennington, New Jersey, United Stateszydususa.com ↗

Ownership: Private
Employees: ~277
Development stage: Commercial

Overview

Zydus Pharmaceuticals is a leading generic pharmaceutical company in the US, offering over 500 SKUs and ranked as the fifth largest unbranded generic corporation based on dispensed prescriptions. The company has received FDA approval for 287 Abbreviated New Drug Applications (ANDAs) and has over 85 ANDAs pending approval[3][5].

Therapeutic areas: OncologyInfectious DiseasesEndocrinologyGastroenterologyCardiovascularNeurologyWomen's Health
Modalities: Small moleculesbiosimilarsvaccinesgenerics
Industry: Biotech

Drug pipeline

3 assets

saroglitazar

Phase 3

Indications: Non-alcoholic steatohepatitis, Primary biliary cholangitis

2 more assets in the full pipeline.

Request access →

Beyond the preview

Go deeper on Zydus Pharmaceuticals.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zydus Pharmaceuticals.

Explore the full profile